Tuberculosis (TB) remains one of the world’s deadliest infectious diseases, despite being both preventable and curable. In 2024 alone, an estimated 10.7 million people fell ill with TB globally, with approximately 1.2–1.3 million deaths reported, making it the leading cause of death from a single infectious agent [1][2]. While progress has been made - particularly in the African region, where deaths have declined since 2015 [3] - the burden remains high, highlighting the urgent need for improved detection and control strategies.
Traditional diagnostic approaches, such as smear microscopy and culture-based methods, have formed the backbone of TB detection for decades. However, these methods are often slow, less sensitive, and dependent on laboratory infrastructure, making them less effective in high-burden or resource-limited settings [4]. Even newer molecular tests, while more accurate, can remain inaccessible due to cost and logistical challenges. As a result, millions of cases are still missed or diagnosed late each year, contributing to ongoing transmission and poor patient outcomes [1].
Recent research is beginning to address these limitations. A newly published study describes a multi-tile diagnostic approach, which integrates multiple analytical signals, rather than relying on a single marker to improve detection accuracy [5]. This method demonstrated improved performance, particularly in complex or low-resource environments where diagnostic variability is high [5]. Such approaches may enhance sensitivity and support more reliable detection in populations that are historically underserved - ultimately improving case finding and enabling more targeted public health responses.
At Hyrax Biosciences, we recognise the importance of advancing TB diagnostics to meet these global challenges. Building on our experience in bioinformatics-driven analysis, we launched our TB solution in 2024 to support laboratories with accurate, scalable, and user-friendly data analysis tools. As the diagnostic landscape continues to evolve, integrating innovative approaches into routine workflows will be key to closing persistent gaps in detection. If your laboratory is interested in exploring our TB analysis solution, you can learn more about the platform here: https://hyraxbio.com/exatype-platform/solutions/, or sign up to try it out for free via Exatype: https://ngs.exatype.com/.
References
- World Health Organization. Tuberculosis Fact Sheet (2025) –
https://www.who.int/news-room/fact-sheets/detail/tuberculosis - WHO Global Tuberculosis Report 2025. 1.1 TB incidence (2025) –
https://www.who.int/teams/global-programme-on-tuberculosis-and-lung-health/tb-reports/global-tuberculosis-report-2025/tb-disease-burden/1-1-tb-incidence - Tuberculosis laboratory capacity building in the WHO African Region: The past, the present and the future: A Viewpoint –
https://pmc.ncbi.nlm.nih.gov/articles/PMC12604794/ - Review: Advances in TB diagnostics –
https://pmc.ncbi.nlm.nih.gov/articles/PMC7733669/ - Journal of Clinical Microbiology (2025). Multi-tile diagnostic approach for TB –
https://journals.asm.org/doi/10.1128/jcm.01823-25
Your sequence data.